XML 25 R11.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 5 - Certain Balance Sheet Accounts | 9 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Supplemental Balance Sheet Disclosures [Text Block] | Note 5 — Certain Balance Sheet Accounts OMIDRIA Contract Royalty Asset The OMIDRIA contract royalty asset consists of the following:
​ |  | September 30, |  |  | December 31, |
​ |  | 2024 |  |  | 2023 |
​ |  | (In thousands) |
Short-term contract royalty asset |  | $ | 29,243 |  |  | $ | 29,373 |
Long-term contract royalty asset |  |  | 129,488 |  |  |  | 138,736 |
Total OMIDRIA contract royalty asset |  | $ | 158,731 |  |  | $ | 168,109 |
See “Note 7 — Discontinued Operations – Sale of OMIDRIA” for discussion regarding the estimated fair value of our OMIDRIA contract royalty asset. Receivables Receivables consist of the following:
​ |  | September 30, |  |  | December 31, |
​ |  | 2024 |  |  | 2023 |
​ |  | (In thousands) |
OMIDRIA royalty receivables |  | $ | 6,095 |  |  | $ | 6,724 |
Other receivables |  |  | 299 |  |  |  | 1,372 |
Total receivables |  | $ | 6,394 |  |  | $ | 8,096 |
Property and Equipment, Net Property and equipment, net consists of the following:
​ |  | September 30, |  |  | December 31, |
​ |  | 2024 |  |  | 2023 |
​ |  | (In thousands) |
Equipment under finance lease obligations |  | $ | 7,309 |  |  | $ | 6,929 |
Laboratory equipment |  |  | 3,664 |  |  |  | 3,525 |
Computer equipment |  |  | 1,113 |  |  |  | 1,113 |
Office equipment and furniture |  |  | 624 |  |  |  | 624 |
Total cost |  |  | 12,710 |  |  |  | 12,191 |
Less accumulated depreciation and amortization |  |  | (10,771 | ) |  |  | (10,241 | )
Total property and equipment, net |  | $ | 1,939 |  |  | $ | 1,950 |
For the three months ended September 30, 2024 and 2023, depreciation and amortization expense was $0.2 million for both periods. For the nine months ended September 30, 2024 and 2023, depreciation and amortization expense was $0.6 million and $0.7 million, respectively. Accrued Expenses Accrued expenses consists of the following:
​ |  | September 30, |  |  | December 31, |
​ |  | 2024 |  |  | 2023 |
​ |  | (In thousands) |
Clinical trials |  | $ | 8,404 |  |  | $ | 10,168 |
Employee compensation |  |  | 6,930 |  |  |  | 7,380 |
Contract research and development |  |  | 4,453 |  |  |  | 6,223 |
Interest payable |  |  | 1,356 |  |  |  | 4,242 |
Consulting and professional fees |  |  | 1,296 |  |  |  | 3,539 |
Other accrued expenses |  |  | 807 |  |  |  | 316 |
Total accrued expenses |  | $ | 23,246 |  |  | $ | 31,868 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration